Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sensex Trades on a Weak Note; Capital Goods Stocks Lead Gains
Thu, 21 Dec 01:30 pm

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line. Sectoral indices are trading mixed with stocks in the banking sector and stocks in the auto sector trading in red. While stocks in the capital goods sector are trading in green.

The BSE Sensex is up by 9 points (up 0.1%) and the NSE Nifty is trading up by 8 points (up 0.1%). Meanwhile, the BSE Mid Cap index is trading up by 0.6%, while the BSE Small Cap index is trading up by 1%. The rupee is trading at 64.05 to the US$.

In news from pharma sector, Cadila Healthcare share price surged 2.3% in noon trade after it was reported that the company's wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received final approval from the United States Food & Drug Administration (USFDA) to market Nifedipine Extended-Release Tablets USP in strengths of 30 mg, 60 mg and 90 mg.

The drug is used to treat hypertension (high blood pressure) and chest pain. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Just Released: Multibagger Stocks Guide
(2018 Edition)

In this report, we reveal four proven strategies to picking multibagger stocks.

Well over a million copies of this report have already been claimed over the years.

Go ahead, grab your copy today. It's Free.

NO-SPAM PLEDGE - We will NEVER rent, sell, or give away your e-mail address to anyone for any reason. You can unsubscribe from The 5 Minute WrapUp with a few clicks. Please read our Privacy Policy & Terms Of Use.

Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.

With an aim to lower the overall healthcare costs in the country, the US Food and Drug Administration (FDA) approved a record 763 generic drugs for the financial year ending 30th September. As per Mint Analysis, Indian pharma companies received 295 approvals accounting for 40% of the overall approvals during the year.

Meanwhile, the BSE Sensex will include Private sector lenders - IndusInd Bank and Yes Bank from December 18, while two pharmaceutical stocks - Cipla and Lupin will exit the index.

Pharma Weightage in BSE Sensex Going Down

With this change, the weight of the pharmaceutical industry in the index declines to a five-year low. As on Friday, four drug makers, namely, Sun Pharma (1.7% weight), Dr Reddy's Laboratories (0.8% weight), Lupin (0.6% weight), and Cipla (0.9% weight) together had a 4% weight in the Sensex. With Cipla and Lupin dropping from the index, the pharmaceutical industry's weight would drop to 2.5%, assuming that the rest of the Sensex stocks remain in the index. And with this, only two pharma companies will represent the Sensex.

Moving on to news from telecom stocks. Reliance Communications (Rcom) share price continued to surge in today's trade as well and was up 10%. The company surged nearly 44% in the previous trade.

The sharp rise in the stock came amid reports that the National Company Law Tribunal (NCLT) adjourned the hearing of insolvency petitions filed against Reliance Communications to early next month.

Meanwhile, the sentiment also remained optimistic ahead of the joint lenders' forum meeting scheduled due later on Thursday. The forum is expected to discuss the bids it has received for sale of the company's assets. According to a Business Standard report, Reliance Jio has been one of the key bidders and has shown interest in both fibre (they are one of the main bulk users) as well as spectrum.

RCom is reeling under a total debt of Rs 450 billion. Of this, Rs 250 billion is domestic debt and remaining Rs 200 billion is in the form of foreign loans and bonds.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Sensex Trades on a Weak Note; Capital Goods Stocks Lead Gains". Click here!